Please assess the completion status of the following clinical trial:

Trial Title: Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Documented symptomatic peripheral arterial disease (one or both of the following two primary criteria must be satisfied):~* Current intermittent claudication with Ankle Brachial Index (ABI) \< 0.90~* A history of intermittent claudication together with previous related intervention in a leg~Exclusion Criteria:~* Patients who had acute atherothrombotic events or any invasive therapies within 30 days before the randomization, or patients who planned any invasive therapies within 12 weeks after the randomization~* Bleeding diathesis, coagulopathy and present bleeding disease~* Previous intracranial bleeding or hemorrhagic stroke~* Uncontrolled hypertension~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: EXPERIMENTAL): 75 mg clopidogrel once daily from Day 1 to Week 12
- Ticlopidine (Type: ACTIVE_COMPARATOR): 200 mg ticlopidine once daily from Day 1 to Week 12

Based on this trial design, predict the completion outcome and termination type (if applicable).